Previous close | 4.0400 |
Open | 4.0800 |
Bid | 4.0900 x 100 |
Ask | 4.1500 x 200 |
Day's range | 4.0500 - 4.1800 |
52-week range | 3.0400 - 8.8000 |
Volume | |
Avg. volume | 167,771 |
Market cap | 203.446M |
Beta (5Y monthly) | 1.48 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.4300 |
Earnings date | 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.83 |
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms. “Spatial biology is transforming drug discovery, translational sciences, and clinical research, and advancing our
KR-HT5 is based on Akoya’s PhenoImager® HT PlatformMARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China's Nation